{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:13Z","timestamp":1792787833532,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"French Health Ministry through North West interregional hospital clinical research program","award":["PHRCI-2022-72"],"award-info":[{"award-number":["PHRCI-2022-72"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14423-2","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T02:57:00Z","timestamp":1751338620000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Homologous recombination deficiency (HRD) tests for ovarian cancer: a multicenter French phase II study (HERO)"],"prefix":"10.1186","volume":"25","author":[{"given":"Rapha\u00ebl","family":"Leman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Cherifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Leheurteur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierrick","family":"Theret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Pasquesoone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Saint-Ghislain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Bresson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Denoyelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Vigneron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Poulain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Delepee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Berby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Dremaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Dumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Blanc-Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Jeanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Briand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis-Ferdinand","family":"Pepin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Deruche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Dumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Leconte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Lequesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Clarisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Castera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Rouzier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"14423_CR1","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495\u2013505.","journal-title":"N Engl J Med"},{"key":"14423_CR2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523\u201333.","journal-title":"N Engl J Med"},{"key":"14423_CR3","doi-asserted-by":"publisher","first-page":"175883591984975","DOI":"10.1177\/1758835919849753","volume":"11","author":"JA Ledermann","year":"2019","unstructured":"Ledermann JA, Pujade-Lauraine E. Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer. Ther Adv Med Oncol. 2019;11:1758835919849753.","journal-title":"Ther Adv Med Oncol"},{"key":"14423_CR4","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1200\/JCO.18.02238","volume":"37","author":"JM Del Campo","year":"2019","unstructured":"Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, et al. Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA trial. J Clin Oncol. 2019;37:2968\u201373.","journal-title":"J Clin Oncol"},{"key":"14423_CR5","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949\u201361.","journal-title":"Lancet"},{"key":"14423_CR6","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, P\u00e9rol D, Gonz\u00e1lez-Mart\u00edn A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416\u201328.","journal-title":"N Engl J Med"},{"key":"14423_CR7","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","volume":"28","author":"PC Fong","year":"2010","unstructured":"Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in brca carrier ovarian cancer correlating with platinum-free interval. JCO. 2010;28:2512\u20139.","journal-title":"JCO"},{"key":"14423_CR8","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ygyno.2019.09.008","volume":"155","author":"SI Labidi-Galy","year":"2019","unstructured":"Labidi-Galy SI, de La Motte Rouge T, Derbel O, Wolfer A, Kalbacher E, Olivier T, et al. Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers. Gynecol Oncol. 2019;155:262\u20139.","journal-title":"Gynecol Oncol"},{"key":"14423_CR9","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1158\/1541-7786.MCR-18-0034","volume":"16","author":"EA Stronach","year":"2018","unstructured":"Stronach EA, Paul J, Timms KM, Hughes E, Brown K, Neff C, et al. Biomarker assessment of HR deficiency, tumor BRCA1\/2 mutations, and CCNE1 copy number in ovarian cancer: associations with clinical outcome following platinum monotherapy. Mol Cancer Res. 2018;16:1103\u201311.","journal-title":"Mol Cancer Res"},{"key":"14423_CR10","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391\u2013402.","journal-title":"N Engl J Med"},{"key":"14423_CR11","doi-asserted-by":"publisher","first-page":"100144","DOI":"10.1016\/j.esmoop.2021.100144","volume":"6","author":"NYL Ngoi","year":"2021","unstructured":"Ngoi NYL, Tan DSP. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it? ESMO Open. 2021;6:100144.","journal-title":"ESMO Open"},{"key":"14423_CR12","doi-asserted-by":"publisher","unstructured":"Leman R, Muller E, Legros A, Goardon N, Chentli I, Atkinson A, et al. Validation of the clinical use of giscar, an academic-developed genomic instability score predicting sensitivity to maintenance olaparib for ovarian cancer. Clin Cancer Res. 2023;29(21):4419\u201329. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0898.","DOI":"10.1158\/1078-0432.CCR-23-0898"},{"key":"14423_CR13","doi-asserted-by":"crossref","unstructured":"Pujade-Lauraine E, Christinat Y, D\u2019incalci M, Schouten P, Buisson A, Heukamp LC et al. 201 homologous recombination deficiency testing in advanced ovarian cancer: description of the ENGOT HRD European initiative. Int J Gynecologic Cancer. 2021;31 Suppl 3.","DOI":"10.1136\/ijgc-2021-ESGO.356"},{"key":"14423_CR14","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/14712598.2017.1340935","volume":"17","author":"V Mandilaras","year":"2017","unstructured":"Mandilaras V, Vernon M, Meryet-Figui\u00e8re M, Karakasis K, Lambert B, Poulain L, et al. Updates and current challenges in MicroRNA research for personalized medicine in ovarian cancer. Expert Opin Biol Ther. 2017;17:927\u201343.","journal-title":"Expert Opin Biol Ther"},{"key":"14423_CR15","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.celrep.2015.12.046","volume":"14","author":"YE Choi","year":"2016","unstructured":"Choi YE, Meghani K, Brault M-E, Leclerc L, He YJ, Day TA, et al. Platinum and PARP inhibitor resistance due to overexpression of MicroRNA-622 in BRCA1-mutant ovarian cancer. Cell Rep. 2016;14:429\u201339.","journal-title":"Cell Rep"},{"key":"14423_CR16","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/clinchem\/hvz013","volume":"66","author":"N Vigneron","year":"2020","unstructured":"Vigneron N, Vernon M, Meryet-Figui\u00e8re M, Lambert B, Briand M, Louis M-H, et al. Predictive relevance of circulating miR-622 in patients with newly diagnosed and recurrent high-grade serous ovarian carcinoma. Clin Chem. 2020;66:352\u201362.","journal-title":"Clin Chem"},{"key":"14423_CR17","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.molonc.2016.03.005","volume":"10","author":"N Vigneron","year":"2016","unstructured":"Vigneron N, Meryet-Figui\u00e8re M, Guttin A, Issartel J-P, Lambert B, Briand M, et al. Towards a new standardized method for circulating MiRNAs profiling in clinical studies: interest of the exogenous normalization to improve MiRNA signature accuracy. Mol Oncol. 2016;10:981\u201392.","journal-title":"Mol Oncol"},{"key":"14423_CR18","doi-asserted-by":"publisher","first-page":"eaaw5473","DOI":"10.1126\/science.aaw5473","volume":"368","author":"B Faubert","year":"2020","unstructured":"Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368:eaaw5473.","journal-title":"Science"},{"key":"14423_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"14423_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3390\/metabo13030417","volume":"13","author":"CF Torkildsen","year":"2023","unstructured":"Torkildsen CF, Austdal M, Iversen A-C, Bathen TF, Giske\u00f8deg\u00e5rd GF, Nilsen EB, et al. Primary treatment effects for high-grade serous ovarian carcinoma evaluated by changes in serum metabolites and lipoproteins. Metabolites. 2023;13:417.","journal-title":"Metabolites"},{"key":"14423_CR21","first-page":"9950","volume":"13","author":"C Nantasupha","year":"2021","unstructured":"Nantasupha C, Thonusin C, Charoenkwan K, Chattipakorn S, Chattipakorn N. Metabolic reprogramming in epithelial ovarian cancer. Am J Transl Res. 2021;13:9950\u201373.","journal-title":"Am J Transl Res"},{"key":"14423_CR22","first-page":"2122","volume":"40","author":"Y Iida","year":"2012","unstructured":"Iida Y, Aoki K, Asakura T, Ueda K, Yanaihara N, Takakura S, et al. Hypoxia promotes glycogen synthesis and accumulation in human ovarian clear cell carcinoma. Int J Oncol. 2012;40:2122\u201330.","journal-title":"Int J Oncol"},{"key":"14423_CR23","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3322\/caac.21670","volume":"71","author":"DR Schmidt","year":"2021","unstructured":"Schmidt DR, Patel R, Kirsch DG, Lewis CA, Vander Heiden MG, Locasale JW. Metabolomics in cancer research and emerging applications in clinical oncology. Cancer J Clin. 2021;71:333\u201358.","journal-title":"Cancer J Clin"},{"key":"14423_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3390\/metabo10100419","volume":"10","author":"A Saorin","year":"2020","unstructured":"Saorin A, Di Gregorio E, Miolo G, Steffan A, Corona G. Emerging role of metabolomics in ovarian cancer diagnosis. Metabolites. 2020;10:419.","journal-title":"Metabolites"},{"key":"14423_CR25","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1021\/acs.jproteome.9b00316","volume":"18","author":"J Debik","year":"2019","unstructured":"Debik J, Euceda LR, Lundgren S, Gythfeldt H, von der L, Garred \u00d8, Borgen E, et al. Assessing treatment response and prognosis by serum and tissue metabolomics in breast cancer patients. J Proteome Res. 2019;18:3649\u201360.","journal-title":"J Proteome Res"},{"key":"14423_CR26","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1158\/0008-5472.CAN-15-2298","volume":"76","author":"M Hilvo","year":"2016","unstructured":"Hilvo M, de Santiago I, Gopalacharyulu P, Schmitt WD, Budczies J, Kuhberg M, et al. Accumulated metabolites of hydroxybutyric acid serve as diagnostic and prognostic biomarkers of ovarian high-grade serous carcinomas. Cancer Res. 2016;76:796\u2013804.","journal-title":"Cancer Res"},{"key":"14423_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223\u201338.","journal-title":"Nat Rev Cancer"},{"key":"14423_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41571-024-00967-y","volume":"22","author":"K Pantel","year":"2025","unstructured":"Pantel K, Alix-Panabi\u00e8res C. Minimal residual disease as a target for liquid biopsy in patients with solid tumours. Nat Rev Clin Oncol. 2025;22:65\u201377.","journal-title":"Nat Rev Clin Oncol"},{"key":"14423_CR29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s10142-023-01181-2","volume":"23","author":"T Xia","year":"2023","unstructured":"Xia T, Fang C, Chen Y. Advances in application of circulating tumor DNA in ovarian cancer. Funct Integr Genomics. 2023;23:250.","journal-title":"Funct Integr Genomics"},{"key":"14423_CR30","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-20-0054","volume":"26","author":"B You","year":"2020","unstructured":"You B, Robelin P, Tod M, Louvet C, Lotz J-P, Abadie-Lacourtoisie S, et al. CA-125 elimination rate constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the phase II CHIVA trial. Clin Cancer Res. 2020;26:4625\u201332.","journal-title":"Clin Cancer Res"},{"key":"14423_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3390\/cancers14010098","volume":"14","author":"A Lauby","year":"2022","unstructured":"Lauby A, Colomban O, Corbaux P, Peron J, Van Wagensveld L, Gertych W, et al. The increasing prognostic and predictive roles of the tumor primary chemosensitivity assessed by CA-125 elimination rate constant K (KELIM) in ovarian cancer: a narrative review. Cancers. 2022;14:98.","journal-title":"Cancers"},{"key":"14423_CR32","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","volume":"34","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2023","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2023;34:833\u201348.","journal-title":"Ann Oncol"},{"key":"14423_CR33","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41592-021-01197-1","volume":"18","author":"S Alseekh","year":"2021","unstructured":"Alseekh S, Aharoni A, Brotman Y, Contrepois K, D\u2019Auria J, Ewald J, et al. Mass spectrometry-based metabolomics: a guide for annotation, quantification and best reporting practices. Nat Methods. 2021;18:747\u201356.","journal-title":"Nat Methods"},{"key":"14423_CR34","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s12885-022-09602-4","volume":"22","author":"H Wen","year":"2022","unstructured":"Wen H, Feng Z, Ma Y, Liu R, Ou Q, Guo Q, et al. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer. BMC Cancer. 2022;22:550.","journal-title":"BMC Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14423-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14423-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14423-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T02:57:02Z","timestamp":1751338622000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14423-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14423"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14423-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has received ethical approval from the\n                      Comit\u00e9 de Protection des Personnes Ile de France IV\n                      in November 2023 (N\u00b0 IDRCB 2023-A01585-40, Ref 23.03705.000286). All patients will be proposed to participate by medical oncologists, who will give them an information file. All patients will give their written informed consent before any study-related assessment start. This study will be performed in accordance with the relevant guidelines and regulations (Declaration of Helsinki).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1075"}}